Scientists from Mass General Brigham have discovered that a blood test may help predict Alzheimer’s disease much earlier than previously thought. This finding could change how doctors identify and manage the disease in the future.
Alzheimer’s disease develops slowly over many years. Before memory loss begins, harmful changes take place in the brain. Proteins such as amyloid and tau start to build up, damaging brain cells. Traditionally, doctors have relied on brain scans to detect these changes, but these scans are costly and not widely available.
The new study, published in Nature Communications, looked at a blood marker called pTau217. This marker is linked to tau protein, which plays a key role in Alzheimer’s disease. When tau becomes abnormal, it forms clumps inside brain cells, interfering with their function.
To better understand this process, researchers followed 317 healthy older adults over eight years. These participants underwent blood testing, brain imaging, and regular cognitive testing. The goal was to see whether pTau217 levels could predict future brain changes and memory decline.
The results showed that people with higher levels of pTau217 were more likely to develop Alzheimer’s-related changes later. These changes included the buildup of amyloid plaques and tau tangles, which are hallmarks of the disease. Interestingly, the increase in pTau217 often happened before brain scans showed any clear signs.
This suggests that the blood test can detect early changes that are not yet visible using standard methods. In contrast, people with low pTau217 levels were less likely to show these brain changes, even after many years.
This discovery is significant because it opens the door to earlier and easier detection. A simple blood test could be used in routine check-ups, making it more accessible for many people. It could also help identify individuals who are suitable for early intervention studies.
The research team believes that this approach could eventually reduce the need for more invasive procedures, such as spinal taps, and expensive imaging tests. It could also allow doctors to monitor disease risk over time using a simple blood sample.
However, experts caution that more work is needed before this test becomes widely used. The study was observational, meaning it tracked changes over time but did not test treatments. Future research will need to confirm these findings and explore how best to use the test in clinical practice.
Another important point is that having a higher pTau217 level does not mean a person will definitely develop Alzheimer’s disease. It only indicates a higher risk. Many factors, including genetics, lifestyle, and overall health, also play a role.
Despite these limitations, the study represents an important step forward. Early detection is one of the biggest challenges in Alzheimer’s research. If doctors can identify risk earlier, they may be able to slow the disease or delay symptoms.
In conclusion, this study highlights the growing potential of blood tests in brain health. While more research is needed, the findings suggest a future where Alzheimer’s disease can be detected earlier, managed better, and possibly prevented.
If you care about Alzheimer’s disease, please read studies that bad lifestyle habits can cause Alzheimer’s disease, and strawberries can be good defence against Alzheimer’s.
For more information about brain health, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Source: Mass General Brigham.
